Articles from Basilea Pharmaceutica AG, Allschwil

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Allschwil, Switzerland, February 05, 2025

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · February 5, 2025

Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea

Allschwil, Switzerland, January 28, 2025

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · January 28, 2025

Basilea provides portfolio update and outlook

Allschwil, Switzerland, January 08, 2025

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · January 8, 2025

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · December 23, 2024

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · December 16, 2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Allschwil, Switzerland, October 10, 2024

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · October 10, 2024

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Allschwil, Switzerland, September 24, 2024

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · September 24, 2024

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · September 19, 2024

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · September 6, 2024

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · August 27, 2024

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, August 21, 2024

By Basilea Pharmaceutica AG, Allschwil · Via GlobeNewswire · August 21, 2024